MedTrace Logo

Tolerability of Lopinavir Versus Dolutegravir for Children and Adolescents Living With HIV

NCT05426421 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 258

Last updated 2025-01-13

No results posted yet for this study

Summary

Dolutegravir-based antiretroviral therapy is set to be increasingly replace ritonavir-boosted lopinavir-based regimens for the treatment of paediatric HIV. This prospective cohort study aims to compare tolerability, adverse effects, and virological outcomes between the two regimen types using a before-after design. The study is conducted in Lesotho, southern Africa, and includes children and adolescents transitioning from ritonavir-boosted lopinavir-based to dolutegravir-based antiretroviral therapy. It aims to provide detailed information on treatment tolerability and to inform paediatric treatment programmes.

Conditions

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • University of Basel

    collaborator OTHER

  • University of Zurich

    collaborator OTHER

  • Baylor International Pediatric AIDS Initiative

    collaborator UNKNOWN

  • Lesotho Ministry of Health

    collaborator UNKNOWN

  • Baylor College of Medicine Children's Foundation Lesotho

    collaborator UNKNOWN

  • Swiss Tropical & Public Health Institute

    lead OTHER

Principal Investigators

  • Jennifer Brown, PhD · University of Basel

  • Akash Devendra, MBChB · Baylor International Paediatric AIDS Initiative

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-11
Primary Completion
2023-09-20
Completion
2023-09-20

Countries

  • Lesotho

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05426421 on ClinicalTrials.gov